Imeka is a neurotechnology company developing advanced neuroimaging analytics focused on diffusion MRI to characterize brain microstructure and white-matter integrity. The company aims to extract clinically meaningful information from complex imaging data to support neurological diagnosis and disease monitoring.

Its platform applies machine learning and advanced diffusion modeling to generate quantitative biomarkers from MRI scans, enabling standardized assessment of brain connectivity and tissue changes. These tools are designed to integrate into existing imaging workflows while improving sensitivity to subtle pathological alterations.

Imeka’s technology is used in clinical research, hospital settings, and pharmaceutical trials, particularly in areas such as multiple sclerosis and other neurological conditions. The company positions its software as a neuroimaging analytics infrastructure layer rather than a hardware imaging provider.